June 2 (Reuters) - Legend Biotech's experimental therapy showed early signs that its approach of generating disease-fighting ...
MedPage Today on MSN
Frontline targeted therapies plus R-CHOP boosts PFS in high-risk B-cell lymphomas
Add-on tafasitamab and lenalidomide did not negatively impact chemotherapy backbone ...
LB2501: Promising Phase 1 Trial of In Vivo CAR-T Data Demonstrate High Response Rates in B-cell Malignancies ...
A retrospective study evaluates the effectiveness of CD19 CAR T-cell therapy in relapsed/refractory B-cell acute lymphoblastic leukemia with extramedullary or CNS disease.
Golcadomide plus standard-of-care chemoimmunotherapy shows potential in improving cure rates among patients with newly ...
PeproMene Bio, Inc. announced today that updated clinical data from its ongoing Phase 1 study evaluating PMB-CT01, an investigational B-cell activating factor receptor (BAFF-R)-targeted CAR T-cell ...
Be Biopharma to Present at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
The abstract highlights Be Biopharma’s approach using both in vitro and in vivo assays to determine the potential of B Cell Medicines (BCMs) as an allogeneic off-the-shelf cell therapy without ...
In patients with autoimmune hemolytic anemia (AIHA), the risk of relapse is high owing to persistent autoreactive B-cell activity. Multirefractory AIHA is a more advanced stage of disease that is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results